查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1831666

處方藥市場，規模，佔有率，趨勢，產業分析報告:各疾病，各地區，2025年～2034年的市場預測

Prescription Drugs Market Size, Share, Trends, & Industry Analysis Report By Ailment (Alzheimer's, Parkinson's, Migraine, Chronic Pain, Sleep Disorders, Major Depressive Disorder), and By Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，預計到 2034 年，處方藥市場規模將達到 2.26 兆美元。本報告深入分析了當前的市場動態，並分析了未來的市場成長。

處方藥可以定義為受監管的藥物，需要獲得醫療保健專業人員的批准才能確保安全有效使用。由於個人化醫療日益受到重視，該市場正在蓬勃發展，個人化醫療正在徹底改變治療設計和處方。處方藥正在擺脫 "一刀切" 的模式，透過根據基因、生活方式和臨床因素量身定制治療方案，更精準地針對特定疾病。這種轉變提高了治療效果，降低了副作用風險，反映了現代醫療保健實踐的變化。

數位健康技術與藥物開發和病患管理的融合進一步推動了處方藥市場的發展。人工智慧、數據分析和互聯健康平台的使用正在簡化藥物研發、臨床試驗和治療依從性監測。這些進步提高了整個價值鏈的效率，同時使患者能夠更有效地管理治療。這些趨勢，加上科學創新和技術進步，正在改善患者的治療效果並重塑處方藥市場。

處方藥市場報告重點

按疾病類別劃分，阿茲海默症預計將在2024年創造最高收入，這得益於老齡化社會中認知能力下降的日益普遍以及對長期治療方案的需求。

預計北美將在2024年以49.57%的佔有率佔全球市場的主導地位，這得益於先進的醫療基礎設施、新療法的高採用率以及對藥物研發的強勁投資。

預計亞太地區將實現最快的成長，這得益於醫療保健支出的增加、處方藥可及性的改善以及注重健康的中產階級的不斷壯大。

全球主要市場參與者包括艾伯維公司 (AbbVie, Inc.)、阿斯特捷利康公司 (AstraZeneca)、百時美施貴寶公司 (Bristol-Myers Squibb Company)、羅氏公司 (F. Hoffmann-La Roche Ltd)、葛蘭素史克公司 (Glaxo Services,.Kline plc.)、強生公司 (Johnson), Johnson. Inc.)、諾華公司 (Novartis AG)、輝瑞公司 (Pfizer, Inc.) 和賽諾菲公司 (Sanofi)。

目錄

第1章 簡介

第2章 摘要整理

第3章 調查手法

第4章 全球處方藥市場洞察

  • 市場概述
  • 處方藥市場動態
    • 促進因素和機會
      • 人口老化
      • 慢性病盛行率上升
    • 高昂的費用和有限的報銷
      • 資料隱私風險
  • PESTEL 分析
  • 處方藥市場趨勢
  • 價值鏈分析

第5章 全球處方藥市場:各疾病

  • 主要調查結果
  • 簡介
  • 阿茲海默症
  • 帕金森氏症
  • 偏頭痛
  • 慢性疼痛
  • 睡眠障礙
  • 重度憂鬱症

第6章 全球處方藥市場:各地區

  • 主要調查結果
  • 簡介
    • 處方藥市場評估:地區，2020～2034年
  • 北美
    • 北美:各疾病，2020～2034年
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲:各疾病，2020～2034年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 亞太地區:各疾病，2020～2034年
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 中東·非洲
    • 中東·非洲:各疾病，2020～2034年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲
  • 南美
    • 南美:各疾病，2020～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美國家

第7章 競爭情形

  • 擴大和收購的分析
    • 擴大
    • 收購
  • 聯盟/合作/協定/公開

第8章 企業簡介

  • AbbVie, Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
Product Code: PM6345

The prescription drugs market size is expected to reach USD 2.26 trillion by 2034, according to a new study by Polaris Market Research. The report "Prescription Drugs Market Share, Size, Trends, Industry Analysis Report: By Ailment (Alzheimer's, Parkinson's, Migraine, Chronic Pain, Sleep Disorders, Major Depressive Disorder), and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Prescription drugs can be defined as regulated medications that require authorization from healthcare professionals to ensure safe and effective use. This market is experiencing growth due to the increasing focus on personalized medicine, which is revolutionizing the design and prescription of treatments. Prescription drugs are moving beyond a "one-size-fits-all" approach and becoming more precise in targeting diseases by tailoring therapies based on genetic, lifestyle, and clinical factors. This transition enhances treatment effectiveness and also reduces the risk of adverse effects, reflecting a shift in modern healthcare practices.

The prescription drugs market is further driven by the integration of digital health technologies into drug development and patient management. The use of artificial intelligence, data analytics, and connected health platforms is streamlining drug discovery, clinical trials, and monitoring of treatment adherence. Such advancements are improving efficiency across the value chain while also empowering patients to manage their therapies more effectively. Together, these trends are reshaping the prescription drugs landscape by combining scientific innovation with technological progress to deliver improved patient outcomes.

Prescription Drugs Market Report Highlights

In terms of ailment, the alzheimer's segment generated the highest revenue in 2024, driven by the increasing prevalence of cognitive decline in aging populations and the necessity for long-term treatment solutions.

North America dominated the global market with a 49.57% share in 2024, attributed to its advanced healthcare infrastructure, high adoption of novel therapies, and strong investment in pharmaceutical R&D.

Asia Pacific region is expected to register the fastest growth rate, propelled by increasing healthcare spending, improved access to prescription drugs, and a growing, health-conscious middle class.

A few global key market players include AbbVie, Inc.; AstraZeneca; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc.; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer, Inc.; and Sanofi.

Polaris Market Research has segmented the market report on the basis of ailment, and region:

By Ailment Outlook (Revenue, USD Trillion, 2020-2034)

Alzheimer's

Parkinson's

Migraine

Chronic pain

Arthritic Pain

Neuropathic Pain

Cancer Pain

Chronic Back Pain

Post-Operative Pain

Fibromyalgia

Bone Fracture

Muscle Pain

Acute Appendicitis

Sleep disorders

Insomnia

Hypersomnia

Sleep Apnea

Sleep Breathing Disorder

Circadian Rhythm Disorders

Parasomnia

Sleep Movement Disorders

Major Depressive Disorder

By Regional Outlook (Revenue, USD Trillion, 2020-2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Prescription Drugs Market Insights

  • 4.1. Prescription Drugs Market - Market Snapshot
  • 4.2. Prescription Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Aging Population
      • 4.2.1.2. Rising Prevalence of Chronic Diseases
    • 4.2.2. High Cost and Limited Reimbursement
      • 4.2.2.1. Data Privacy Risk
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Prescription Drugs Market Trends
  • 4.6. Value Chain Analysis

5. Global Prescription Drugs Market, by Ailment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 5.3. Alzheimer's
    • 5.3.1. Global Prescription Drugs Market, by Alzheimer's, by Region, 2020-2034 (USD Billion)
  • 5.4. Parkinson's
    • 5.4.1. Global Prescription Drugs Market, by Parkinson's, by Region, 2020-2034 (USD Billion)
  • 5.5. Migraine
    • 5.5.1. Global Prescription Drugs Market, by Migraine, by Region, 2020-2034 (USD Billion)
  • 5.6. Chronic pain
    • 5.6.1. Global Prescription Drugs Market, by Chronic Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.2. Arthritic Pain
      • 5.6.2.1. Global Prescription Drugs Market, by Arthritic Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.3. Neuropathic Pain
      • 5.6.3.1. Global Prescription Drugs Market, by Neuropathic Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.4. Cancer Pain
      • 5.6.4.1. Global Prescription Drugs Market, by Cancer Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.5. Chronic Back Pain
      • 5.6.5.1. Global Prescription Drugs Market, by Chronic Back Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.6. Post-Operative Pain
      • 5.6.6.1. Global Prescription Drugs Market, by Post-Operative Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.7. Fibromyalgia
      • 5.6.7.1. Global Prescription Drugs Market, by Fibromyalgia, by Region, 2020-2034 (USD Billion)
    • 5.6.8. Bone Fracture
      • 5.6.8.1. Global Prescription Drugs Market, by Bone Fracture, by Region, 2020-2034 (USD Billion)
    • 5.6.9. Muscle Pain
      • 5.6.9.1. Global Prescription Drugs Market, by Muscle Pain, by Region, 2020-2034 (USD Billion)
    • 5.6.10. Acute Appendicitis
      • 5.6.10.1. Global Prescription Drugs Market, by Acute Appendicitis, by Region, 2020-2034 (USD Billion)
  • 5.7. Sleep Disorders
    • 5.7.1. Global Prescription Drugs Market, by Sleep Disorders Products, by Region, 2020-2034 (USD Billion)
    • 5.7.2. Insomnia
      • 5.7.2.1. Global Prescription Drugs Market, by Insomnia, by Region, 2020-2034 (USD Billion)
    • 5.7.3. Hypersomnia
      • 5.7.3.1. Global Prescription Drugs Market, by Hypersomnia, by Region, 2020-2034 (USD Billion)
    • 5.7.4. Sleep Apnea
      • 5.7.4.1. Global Prescription Drugs Market, by Sleep Apnea, by Region, 2020-2034 (USD Billion)
    • 5.7.5. Sleep Breathing Disorder
      • 5.7.5.1. Global Prescription Drugs Market, by Sleep Breathing Disorder, by Region, 2020-2034 (USD Billion)
    • 5.7.6. Circadian Rhythm Disorders
      • 5.7.6.1. Global Prescription Drugs Market, by Circadian Rhythm Disorders, by Region, 2020-2034 (USD Billion)
    • 5.7.7. Parasomnia
      • 5.7.7.1. Global Prescription Drugs Market, by Parasomnia, by Region, 2020-2034 (USD Billion)
    • 5.7.8. Sleep Movement Disorders
      • 5.7.8.1. Global Prescription Drugs Market, by Sleep Movement Disorders, by Region, 2020-2034 (USD Billion)
  • 5.8. Major Depressive Disorders
    • 5.8.1. Global Prescription Drugs Market, by Major Depressive Disorders, by Region, 2020-2034 (USD Billion)

6. Global Prescription Drugs Market, by Geography

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Prescription Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 6.3. Prescription Drugs Market - North America
    • 6.3.1. North America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.3.2. Prescription Drugs Market - U.S.
      • 6.3.2.1. U.S.: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.3.3. Prescription Drugs Market - Canada
      • 6.3.3.1. Canada: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 6.4. Prescription Drugs Market - Europe
    • 6.4.1. Europe: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.2. Prescription Drugs Market - UK
      • 6.4.2.1. UK: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.3. Prescription Drugs Market - France
      • 6.4.3.1. France: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.4. Prescription Drugs Market - Germany
      • 6.4.4.1. Germany: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.5. Prescription Drugs Market - Italy
      • 6.4.5.1. Italy: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.6. Prescription Drugs Market - Spain
      • 6.4.6.1. Spain: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.7. Prescription Drugs Market - Netherlands
      • 6.4.7.1. Netherlands: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.8. Prescription Drugs Market - Russia
      • 6.4.8.1. Russia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.4.9. Prescription Drugs Market - Rest of Europe
      • 6.4.9.1. Rest of Europe: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 6.5. Prescription Drugs Market - Asia Pacific
    • 6.5.1. Asia Pacific: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.2. Prescription Drugs Market - China
      • 6.5.2.1. China: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.3. Prescription Drugs Market - India
      • 6.5.3.1. India: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.4. Prescription Drugs Market - Malaysia
      • 6.5.4.1. Malaysia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.5. Prescription Drugs Market - Japan
      • 6.5.5.1. Japan: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.6. Prescription Drugs Market - Indonesia
      • 6.5.6.1. Indonesia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.7. Prescription Drugs Market - South Korea
      • 6.5.7.1. South Korea: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.8. Prescription Drugs Market - Australia
      • 6.5.8.1. Australia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.5.9. Prescription Drugs Market - Rest of Asia Pacific
      • 6.5.9.1. Rest of Asia Pacific: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 6.6. Prescription Drugs Market - Middle East & Africa
    • 6.6.1. Middle East & Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.2. Prescription Drugs Market - Saudi Arabia
      • 6.6.2.1. Saudi Arabia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.3. Prescription Drugs Market - UAE
      • 6.6.3.1. UAE: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.4. Prescription Drugs Market - Israel
      • 6.6.4.1. Israel: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.5. Prescription Drugs Market - South Africa
      • 6.6.5.1. South Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.6.6. Prescription Drugs Market - Rest of Middle East & Africa
      • 6.6.6.1. Rest of Middle East & Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • 6.7. Prescription Drugs Market - Latin America
    • 6.7.1. Latin America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.7.2. Prescription Drugs Market - Mexico
      • 6.7.2.1. Mexico: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.7.3. Prescription Drugs Market - Brazil
      • 6.7.3.1. Brazil: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.7.4. Prescription Drugs Market - Argentina
      • 6.7.4.1. Argentina: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
    • 6.7.5. Prescription Drugs Market - Rest of Latin America
      • 6.7.5.1. Rest of Latin America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)

7. Competitive Landscape

  • 7.1. Expansion and Acquisition Analysis
    • 7.1.1. Expansion
    • 7.1.2. Acquisitions
  • 7.2. Partnerships/Collaborations/Agreements/Exhibitions

8. Company Profiles

  • 8.1. AbbVie, Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Financial Performance
    • 8.1.3. Product Benchmarking
    • 8.1.4. Recent Development
  • 8.2. AstraZeneca
    • 8.2.1. Company Overview
    • 8.2.2. Financial Performance
    • 8.2.3. Product Benchmarking
    • 8.2.4. Recent Development
  • 8.3. Bristol-Myers Squibb Company
    • 8.3.1. Company Overview
    • 8.3.2. Financial Performance
    • 8.3.3. Product Benchmarking
    • 8.3.4. Recent Development
  • 8.4. F. Hoffmann-La Roche Ltd
    • 8.4.1. Company Overview
    • 8.4.2. Financial Performance
    • 8.4.3. Product Benchmarking
    • 8.4.4. Recent Development
  • 8.5. GlaxoSmithKline plc.
    • 8.5.1. Company Overview
    • 8.5.2. Financial Performance
    • 8.5.3. Product Benchmarking
    • 8.5.4. Recent Development
  • 8.6. Johnson & Johnson Services, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Financial Performance
    • 8.6.3. Product Benchmarking
    • 8.6.4. Recent Development
  • 8.7. Merck & Co., Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Financial Performance
    • 8.7.3. Product Benchmarking
    • 8.7.4. Recent Development
  • 8.8. Novartis AG
    • 8.8.1. Company Overview
    • 8.8.2. Financial Performance
    • 8.8.3. Product Benchmarking
    • 8.8.4. Recent Development
  • 8.9. Pfizer, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Financial Performance
    • 8.9.3. Product Benchmarking
    • 8.9.4. Recent Development
  • 8.10. Sanofi
    • 8.10.1. Company Overview
    • 8.10.2. Financial Performance
    • 8.10.3. Product Benchmarking
    • 8.10.4. Recent Development

List of Tables:

  • Table 1 Global Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 2 North America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 3 U.S.: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 4 Canada: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 5 Europe: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 6 UK: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 7 France: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 8 Germany: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 9 Italy: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 10 Spain: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 11 Netherlands: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 12 Russia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 13 Rest of Europe: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 14 Asia Pacific: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 15 China: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 16 India: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 17 Malaysia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 18 Japan: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 19 Indonesia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 20 South Korea: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 21 Australia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 22 Rest of Asia Pacific: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 23 Middle East & Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 24 Saudi Arabia: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 25 UAE: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 26 Israel: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 27 South Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 28 Rest of Middle East & Africa: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 29 Latin America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 30 Mexico: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 31 Brazil: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 32 Argentina: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)
  • Table 33 Rest of Latin America: Prescription Drugs Market, by Ailment, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Prescription Drugs Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Ailment
  • Figure 7. Global Prescription Drugs Market, by Ailment, 2024 & 2034 (USD Billion)